These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 16978222)

  • 1. Exisulind induces apoptosis in advanced myelodysplastic syndrome (MDS) and acute myeloid leukaemia/MDS.
    Czibere A; Prall WC; Zerbini LF; Jäger M; Kobbe G; Knipp S; Libermann TA; Haas R; Aivado M
    Br J Haematol; 2006 Nov; 135(3):355-7. PubMed ID: 16978222
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The nonsteroidal anti-inflammatory drug Exisulind selectively induces apoptosis via JNK in secondary acute myeloid leukemia after myelodysplastic syndrome.
    Czibere A; Prall WC; Zerbini LF; Grall F; Craigie EC; Ulrich SD; Giagounidis AA; Haas R; Libermann TA; Aivado M
    Cell Cycle; 2005 Jun; 4(6):812-7. PubMed ID: 15970671
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alpha-tocopheryl succinate sensitizes human colon cancer cells to exisulind-induced apoptosis.
    Lim SJ; Lee YJ; Park DH; Lee E; Choi MK; Park W; Chun KH; Choi HG; Cho JS
    Apoptosis; 2007 Feb; 12(2):423-31. PubMed ID: 17191116
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Akt/mammalian target of rapamycin signal transduction pathway is activated in high-risk myelodysplastic syndromes and influences cell survival and proliferation.
    Follo MY; Mongiorgi S; Bosi C; Cappellini A; Finelli C; Chiarini F; Papa V; Libra M; Martinelli G; Cocco L; Martelli AM
    Cancer Res; 2007 May; 67(9):4287-94. PubMed ID: 17483341
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular pathways in myelodysplastic syndromes and acute myeloid leukemia: relationships and distinctions-a review.
    Bernasconi P
    Br J Haematol; 2008 Sep; 142(5):695-708. PubMed ID: 18540941
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Myelodysplastic syndromes: the complexity of stem-cell diseases.
    Corey SJ; Minden MD; Barber DL; Kantarjian H; Wang JC; Schimmer AD
    Nat Rev Cancer; 2007 Feb; 7(2):118-29. PubMed ID: 17251918
    [TBL] [Abstract][Full Text] [Related]  

  • 7. JNK and ERK mitogen-activated protein kinases mediate THDA-induced apoptosis in K562 cells.
    Yang SH; Wu ZZ; Chien CM; Lo YH; Wu MJ; Chang LS; Lin SR
    Cell Biol Toxicol; 2008 Aug; 24(4):291-302. PubMed ID: 17934787
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of NEMO, the regulatory subunit of the IKK complex, induces apoptosis in high-risk myelodysplastic syndrome and acute myeloid leukemia.
    Carvalho G; Fabre C; Braun T; Grosjean J; Ades L; Agou F; Tasdemir E; Boehrer S; Israel A; Véron M; Fenaux P; Kroemer G
    Oncogene; 2007 Apr; 26(16):2299-307. PubMed ID: 17043643
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NF-kappaB inhibition sensitizes to starvation-induced cell death in high-risk myelodysplastic syndrome and acute myeloid leukemia.
    Fabre C; Carvalho G; Tasdemir E; Braun T; Adès L; Grosjean J; Boehrer S; Métivier D; Souquère S; Pierron G; Fenaux P; Kroemer G
    Oncogene; 2007 Jun; 26(28):4071-83. PubMed ID: 17213804
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The non-steroidal anti-inflammatory drugs Sulindac sulfide and Diclofenac induce apoptosis and differentiation in human acute myeloid leukemia cells through an AP-1 dependent pathway.
    Singh R; Cadeddu RP; Fröbel J; Wilk CM; Bruns I; Zerbini LF; Prenzel T; Hartwig S; Brünnert D; Schroeder T; Lehr S; Haas R; Czibere A
    Apoptosis; 2011 Sep; 16(9):889-901. PubMed ID: 21739277
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacodynamic monitoring of BAY 43-9006 (Sorafenib) in phase I clinical trials involving solid tumor and AML/MDS patients, using flow cytometry to monitor activation of the ERK pathway in peripheral blood cells.
    Tong FK; Chow S; Hedley D
    Cytometry B Clin Cytom; 2006 May; 70(3):107-14. PubMed ID: 16498671
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overexpression of the Doppel protein in acute myeloid leukaemias and myelodysplastic syndromes.
    Travaglino E; Comincini S; Benatti C; Azzalin A; Nano R; Rosti V; Ferretti L; Invernizzi R
    Br J Haematol; 2005 Mar; 128(6):877-84. PubMed ID: 15755294
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biological and clinical relevance of matrix metalloproteinases 2 and 9 in acute myeloid leukaemias and myelodysplastic syndromes.
    Travaglino E; Benatti C; Malcovati L; Della Porta MG; Gallì A; Bonetti E; Rosti V; Cazzola M; Invernizzi R
    Eur J Haematol; 2008 Mar; 80(3):216-26. PubMed ID: 18081721
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Results of a multicenter phase II trial for older patients with c-Kit-positive acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR-MDS) using low-dose Ara-C and Imatinib.
    Heidel F; Cortes J; Rücker FG; Aulitzky W; Letvak L; Kindler T; Huber C; Döhner H; Kantarjian H; Fischer T
    Cancer; 2007 Mar; 109(5):907-14. PubMed ID: 17285599
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Indomethacin induces apoptosis in 786-O renal cell carcinoma cells by activating mitogen-activated protein kinases and AKT.
    Ou YC; Yang CR; Cheng CL; Raung SL; Hung YY; Chen CJ
    Eur J Pharmacol; 2007 Jun; 563(1-3):49-60. PubMed ID: 17341418
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Apoptosis as a cell biological abnormality in myelodysplasia.
    Yoshida Y; Kawabata H; Anzai N; Tohyama K
    Pathol Biol (Paris); 1997 Sep; 45(7):573-8. PubMed ID: 9404482
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular pathways mediating MDS/AML with focus on AML1/RUNX1 point mutations.
    Harada Y; Harada H
    J Cell Physiol; 2009 Jul; 220(1):16-20. PubMed ID: 19334039
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Histopathology in the diagnosis and classification of acute myeloid leukemia, myelodysplastic syndromes, and myelodysplastic/myeloproliferative diseases.
    Orazi A
    Pathobiology; 2007; 74(2):97-114. PubMed ID: 17587881
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Arsenic disulfide-triggered apoptosis and erythroid differentiation in myelodysplastic syndrome and acute myeloid leukemia cell lines.
    Hu XM; Yuan B; Tanaka S; Song MM; Onda K; Tohyama K; Zhou AX; Toyoda H; Hirano T
    Hematology; 2014 Sep; 19(6):352-60. PubMed ID: 24192507
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anthracyclines, mitoxantrone, radiotherapy, and granulocyte colony-stimulating factor: risk factors for leukemia and myelodysplastic syndrome after breast cancer.
    Le Deley MC; Suzan F; Cutuli B; Delaloge S; Shamsaldin A; Linassier C; Clisant S; de Vathaire F; Fenaux P; Hill C
    J Clin Oncol; 2007 Jan; 25(3):292-300. PubMed ID: 17159192
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.